Key Highlights
- Net loss per share was USD 0.49 against an estimate of a USD 0.61 loss.
- Net loss was USD 5.54 million, compared with USD 0.35 million.
- Total operating expenses were USD 5.95 million, compared with USD 0.29 million.
- Cash and cash equivalents were USD 56.26 million at September 30, 2026.
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported a net loss of USD 5.54 million for the third quarter of 2026, compared with USD 0.35 million in the third quarter of 2025. The net loss per share was USD 0.49, compared with USD 0.58, against an estimate of a USD 0.61 loss.
The Quarterly Report did not state a Revenue figure for the period.
Operating Expenses
Research and development expense was USD 4.03 million, compared with a Credit of USD 0.25 million in the prior-year quarter. General and administrative expense was USD 1.93 million, compared with USD 0.54 million; the filing states that the increase was USD 1.4 million. Total operating expenses, which equal the loss from operations, were USD 5.95 million, compared with USD 0.29 million.
Other income, net, was USD 0.41 million, compared with other expense, net, of USD 0.07 million.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 13.80 million, compared with USD 3.95 million, and the net loss per share was USD 1.83, compared with USD 9.12. Research and Development expense was USD 8.53 million, compared with USD 1.16 million, and general and administrative expense was USD 5.67 million, compared with USD 1.93 million. Total operating expenses were USD 14.20 million, compared with USD 3.09 million.
Balance Sheet and Liquidity
Cash and cash equivalents were USD 56.26 million at September 30, 2026, compared with USD 4.79 million at December 31, 2025. Total Assets were USD 58.26 million, compared with USD 5.27 million, and total current liabilities were USD 17.19 million, compared with USD 17.18 million. Total stockholders' Equity was USD 41.07 million, compared with a Deficit of USD 11.91 million.
The company states that its cash and cash equivalents of USD 56.3 million are sufficient to maintain its current and planned operations for at least the next twelve months following the filing of the report. In June 2026, it completed an uplisting to the Nasdaq Capital Market alongside a public offering, with issuance costs of USD 7.6 million.
Weighted average shares of common stock and pre-funded warrants used in computing net loss per share were 11,404,791 for the quarter, compared with 604,278. The company had 4,086,611 shares of common stock issued and outstanding at September 30, 2026, compared with 435,432 at December 31, 2025. In connection with the June 2026 public offering, it recorded USD 58.32 million from the issuance of common stock and pre-funded warrants, net of issuance costs.
Additional paid-in capital was USD 355.41 million, compared with USD 288.69 million, and the accumulated deficit was USD 314.38 million, compared with USD 300.58 million. Advances from collaboration partners, net of Debt discount, were USD 11.84 million, compared with USD 11.82 million, accrued expenses were USD 2.83 million, compared with USD 1.61 million, and Warrant liabilities were USD 0.10 million.
Eloxx Pharmaceuticals Q3 2026 Earnings: Key Takeaways
Eloxx Pharmaceuticals reported a third quarter 2026 net loss of USD 5.54 million and a loss per share of USD 0.49. Cash and cash equivalents were USD 56.26 million at September 30, 2026.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...